174 related articles for article (PubMed ID: 37467311)
21. [A case of mental retardation caused by a frameshift variant of SYNGAP1 gene].
Shen Y; Luo G; Lu C; Tan Y; Cheng T; Qian X; Li N; Luo M; Cao Z; Ma X; Zhao Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2023 Jan; 40(1):57-61. PubMed ID: 36585002
[TBL] [Abstract][Full Text] [Related]
22. Visual social attention in SYNGAP1-related intellectual disability.
Wright D; Kenny A; Eley S; McKechanie AG; Stanfield AC
Autism Res; 2024 Jun; 17(6):1083-1093. PubMed ID: 38698724
[TBL] [Abstract][Full Text] [Related]
23. Clinical and behavioural features of SYNGAP1-related intellectual disability: a parent and caregiver description.
Wright D; Kenny A; Eley S; McKechanie AG; Stanfield AC
J Neurodev Disord; 2022 Jun; 14(1):34. PubMed ID: 35655128
[TBL] [Abstract][Full Text] [Related]
24. [Autosomal dominant mental retardation type 5 caused by
Wang XL; Tian YN; Chen C; Peng J
Zhongguo Dang Dai Er Ke Za Zhi; 2023 May; 25(5):489-496. PubMed ID: 37272175
[TBL] [Abstract][Full Text] [Related]
25. Differential auditory brain response abnormalities in two intellectual disability conditions: SYNGAP1 mutations and Down syndrome.
Côté V; Knoth IS; Agbogba K; Vannasing P; Côté L; Major P; Michaud JL; Barlaam F; Lippé S
Clin Neurophysiol; 2021 Aug; 132(8):1802-1812. PubMed ID: 34130248
[TBL] [Abstract][Full Text] [Related]
26. De novo missense variants in MEIS2 recapitulate the microdeletion phenotype of cardiac and palate abnormalities, developmental delay, intellectual disability and dysmorphic features.
Douglas G; Cho MT; Telegrafi A; Winter S; Carmichael J; Zackai EH; Deardorff MA; Harr M; Williams L; Psychogios A; Erwin AL; Grebe T; Retterer K; Juusola J
Am J Med Genet A; 2018 Sep; 176(9):1845-1851. PubMed ID: 30055086
[TBL] [Abstract][Full Text] [Related]
27. Phenotype and genotype analyses of Chinese patients with autosomal dominant mental retardation type 5 caused by
Wang Y; Lv Y; Li Z; Gao M; Yang X; Li Y; Shi J; Gao Z; Liu Y; Gai Z
Front Genet; 2022; 13():957915. PubMed ID: 36583017
[No Abstract] [Full Text] [Related]
28. SYNGAP1 Mutation in Focal and Generalized Epilepsy: A Literature Overview and A Case Report with Special Aspects of the EEG.
von Stülpnagel C; Funke C; Haberl C; Hörtnagel K; Jüngling J; Weber YG; Staudt M; Kluger G
Neuropediatrics; 2015 Aug; 46(4):287-91. PubMed ID: 26110312
[TBL] [Abstract][Full Text] [Related]
29. Whole exome sequencing is necessary to clarify ID/DD cases with de novo copy number variants of uncertain significance: Two proof-of-concept examples.
Giorgio E; Ciolfi A; Biamino E; Caputo V; Di Gregorio E; Belligni EF; Calcia A; Gaidolfi E; Bruselles A; Mancini C; Cavalieri S; Molinatto C; Cirillo Silengo M; Ferrero GB; Tartaglia M; Brusco A
Am J Med Genet A; 2016 Jul; 170(7):1772-9. PubMed ID: 27108886
[TBL] [Abstract][Full Text] [Related]
30. Whole exome sequencing revealed variants in four genes underlying X-linked intellectual disability in four Iranian families: novel deleterious variants and clinical features with the review of literature.
Mir A; Song Y; Lee H; Khanahmad H; Khorram E; Nasiri J; Tabatabaiefar MA
BMC Med Genomics; 2023 Oct; 16(1):239. PubMed ID: 37821930
[TBL] [Abstract][Full Text] [Related]
31. Novel variants underlying autosomal recessive neurodevelopmental disorders with intellectual disability in Iranian consanguineous families.
Moudi M; Vahidi Mehrjardi MY; Hozhabri H; Metanat Z; Kalantar SM; Taheri M; Ghasemi N; Dehghani M
J Clin Lab Anal; 2022 Feb; 36(2):e24241. PubMed ID: 35019165
[TBL] [Abstract][Full Text] [Related]
32. Confirmation of chromosomal microarray as a first-tier clinical diagnostic test for individuals with developmental delay, intellectual disability, autism spectrum disorders and dysmorphic features.
Battaglia A; Doccini V; Bernardini L; Novelli A; Loddo S; Capalbo A; Filippi T; Carey JC
Eur J Paediatr Neurol; 2013 Nov; 17(6):589-99. PubMed ID: 23711909
[TBL] [Abstract][Full Text] [Related]
33. The first international conference on SYNGAP1-related brain disorders: a stakeholder meeting of families, researchers, clinicians, and regulators.
Weldon M; Kilinc M; Lloyd Holder J; Rumbaugh G
J Neurodev Disord; 2018 Feb; 10(1):6. PubMed ID: 29402231
[TBL] [Abstract][Full Text] [Related]
34. Identification of a novel de novo mutation in the CTNNB1 gene in an Iranian patient with intellectual disability.
Dashti S; Salehpour S; Ghasemi MR; Sadeghi H; Rostami M; Hashemi-Gorji F; Mirfakhraie R; Yassaee VR; Miryounesi M
Neurol Sci; 2022 Apr; 43(4):2859-2863. PubMed ID: 35099645
[TBL] [Abstract][Full Text] [Related]
35. A novel
Shakarami F; Nouri Z; Khanahmad H; Ghazavi M; Amin Tabatabaiefar M
J Genet; 2023; 102():. PubMed ID: 37731250
[TBL] [Abstract][Full Text] [Related]
36. Genetic characterization of Schuurs-Hoeijmakers syndrome in a moroccan individual with heterozygote PACS1 mutation.
Abbassi M; Bourmtane A; Sayel H; El Mouhi H; Jalte M; Elasri YA; Askander O; El Fahime E; Bouguenouch L
Mol Biol Rep; 2023 Nov; 50(11):9121-9128. PubMed ID: 37747683
[TBL] [Abstract][Full Text] [Related]
37. A novel RAB39B mutation and concurrent de novo NF1 mutation in a boy with neurofibromatosis type 1, intellectual disability, and autism: a case report.
Santoro C; Giugliano T; Bernardo P; Palladino F; Torella A; Del Vecchio Blanco F; Onore ME; Carotenuto M; Nigro V; Piluso G
BMC Neurol; 2020 Sep; 20(1):327. PubMed ID: 32873259
[TBL] [Abstract][Full Text] [Related]
38. Species-conserved SYNGAP1 phenotypes associated with neurodevelopmental disorders.
Kilinc M; Creson T; Rojas C; Aceti M; Ellegood J; Vaissiere T; Lerch JP; Rumbaugh G
Mol Cell Neurosci; 2018 Sep; 91():140-150. PubMed ID: 29580901
[TBL] [Abstract][Full Text] [Related]
39. De novo and inherited TCF20 pathogenic variants are associated with intellectual disability, dysmorphic features, hypotonia, and neurological impairments with similarities to Smith-Magenis syndrome.
Vetrini F; McKee S; Rosenfeld JA; Suri M; Lewis AM; Nugent KM; Roeder E; Littlejohn RO; Holder S; Zhu W; Alaimo JT; Graham B; Harris JM; Gibson JB; Pastore M; McBride KL; Komara M; Al-Gazali L; Al Shamsi A; Fanning EA; Wierenga KJ; Scott DA; Ben-Neriah Z; Meiner V; Cassuto H; Elpeleg O; Holder JL; Burrage LC; Seaver LH; Van Maldergem L; Mahida S; Soul JS; Marlatt M; Matyakhina L; Vogt J; Gold JA; Park SM; Varghese V; Lampe AK; Kumar A; Lees M; Holder-Espinasse M; McConnell V; Bernhard B; Blair E; Harrison V; ; Muzny DM; Gibbs RA; Elsea SH; Posey JE; Bi W; Lalani S; Xia F; Yang Y; Eng CM; Lupski JR; Liu P
Genome Med; 2019 Feb; 11(1):12. PubMed ID: 30819258
[TBL] [Abstract][Full Text] [Related]
40. Lovastatin Treatment of a Patient with a
Cook EH; Masaki JT; Guter SJ; Najjar F
J Child Adolesc Psychopharmacol; 2019 May; 29(4):321-322. PubMed ID: 30901256
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
